Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Lion Biotechnologies Inc (LBIO): Ayer Capital Management Halves Its Stake

Biotech stocks have been in the middle of everyone’s attention lately and many have gained impressive ground (often not justified by the company’s lack of revenue and huge losses). In this way, some investors are picking profits, such as Jay Venkatesen‘s Ayer Capital Management, which has sold 2.78 million shares of Lion Biotechnologies Inc (NASDAQ:LBIO) and slashed its stake to 2.82 million shares, representing around 6.30% of the company’s outstanding stock. As Ayer disclosed in the filing, it sold the shares in one transaction at $9.63 per unit.


Ayer’s transaction was a part of an underwritten secondary offering that involved $4.75 million shares of Lion Biotechnologies Inc (NASDAQ:LBIO) with a 0.375 gross spread to the underwriters. The securities were sold only by stockholders, including members of the board, while Lion Biotechnologies has not disposed of any shares and therefore has not received any proceeds.

Lion Biotechnologies Inc (NASDAQ:LBIO) is a $484 million development-stage biotechnology company, whose stock surged by 36% since the beginning of the year. It represented the largest position in Ayer Capital’s equity portfolio at the end of March, the only other holding being a 250,000 shares in Oncothyreon Inc (USA) (NASDAQ:ONTY), a clinical-stage biopharmaceutical company, whose stock is up by 25% year-to-date.

Other shareholders of Lion Biotechnologies Inc (NASDAQ:LBIO) include Daniel Gold’s QVT Financial and Baker Bros. Advisors, which initiated stakes with 1.33 million shares each during the first quarter. Kevin Kotler‘s Broadfin Capital also disclosed a new position with 1.06 million shares in its latest 13F filing.

Disclosure: none

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!